An order asking Yoga guru Ramdev's Divya Pharmacy to stop the production of five medicines for diabetes, blood pressure, goitre, glaucoma and high cholesterol has been revoked by the Uttarakhand Ayurveda and Unani Licensing Authority.
Amending the earlier order, the authority on Saturday issued a fresh one allowing the firm to continue the production of these medicines.
-
The Mystery Of A Bare Nail In Ashwini Vaishnaw's Office -
Paris Setback, Asian Games Glory: Lovlina Borgohain's New Perspective -
To PM Modi's "Failed Product" Jab At Rahul Gandhi, A Shashi Tharoor Counter -
NDTV World Summit 2026: AI, Chips, Warfare And The Future Of The World | Key Conversations -
Kriti Sanon On Situationships, Open Relationships And Being Old-School -
'AI Scares Me': Kriti Sanon On Personality Rights And Need For Laws -
'AI Scares Me': Kriti Sanon On Personality Rights And Need For Laws -
'This Time I Wanted Gold': Savita Punia Reflects On Historic Asiad Success -
Favourite Bollywood Actor To 5-Year Plan, Kriti Sanon Interviews AI Actor Tilly Norwood -
Inside The Mind Of Archer Kumkum Mohod, Who Dared To Challenge South Korea
Observing that there was an error in the previous order dated November 9, the drug controller of the state health authority GCN Jangpangi said it had been issued in haste. "We should have given the company time to explain its stand before issuing the order," Mr Jangpangi said.
Ramdev's close aide Acharya Balkrishna expressed his gratitude to the state government for rectifying the error. In its earlier order, the Authority had asked Divya Pharmacy to stop the production of five of its products -- Bpgrit, Madhugrit, Thyrogrit, Lipidom tablets and Eyegrit Gold tablets -- which were being promoted as medicines for blood pressure, diabetes, goitre, glaucoma and high cholesterol.
उत्तराखण्ड सरकार ने मानी गलती, पतंजलि की पाँचों दवाओं पर लगा बैन हटाया !
- Acharya Balkrishna (@Ach_Balkrishna) November 12, 2022
पतंजलि संस्थान ने विश्व में सर्वप्रथम आयुर्वेद की औषधियों को 30 वर्षों के निरन्तर पुरुषार्थ व अनुसंधान से Research and evidence based medicine के रूप में स्वीकार्यता दिलाई। pic.twitter.com/85oWOV6co7
The previous order said the company can restart manufacturing these products only after the authority approves their revised formulation sheets.
The action was taken following a complaint filed by a doctor from Kerala, KV Babu, in which he had accused Divya Pharmacy of violating the Drugs and Magic Remedies (objectionable advertisement) Act and Drugs and Cosmetic Act.
Babu had lodged his complaint against the firm with the Authority in July and followed it up with another via email on October 11.
Track Latest News Live on NDTV.com and get news updates from India and around the world